---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-045844"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2026-10-06T11:30:06+00:00"
generated_at: "2026-10-12T16:36:23.164678+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma reports ENV-105 plus apalutamide median PFS of 17.7 months vs 2 months in Phase 2 mCRPC trial (P=0.0008)

## Summary
- Interim Phase 2 analysis showed a statistically significant PFS difference for ENV-105 plus apalutamide vs apalutamide alone (median 17.7 vs 2 months; P=0.0008).
- Kairos modified the Phase 2 protocol to enroll patients earlier, after PSA increase on an androgen signaling inhibitor, randomized to enzalutamide alone or with ENV-105.
- The company targets completion of the Phase 2 trial in or before Q4 2027; CEO John Yu called the interim results an important clinical signal for ENV-105.
- Patients were enrolled at Cedars-Sinai Medical Center, City of Hope and Huntsman Cancer Institute at the University of Utah.
- ENV-105 (carotuximab) targets CD105, which Kairos describes as a key driver of resistance and relapse after standard cancer therapy.

## SEC filing metadata
- accession: 0001493152-26-045844
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2026-10-06T11:30:06+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315226045844/0001493152-26-045844-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315226045844/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-045844
- JSON: https://secwatch.observer/filing/0001493152-26-045844.json
- Plain text: https://secwatch.observer/filing/0001493152-26-045844.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.